Quote | Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN)
Last: | $1.77 |
---|---|
Change Percent: | 0.0% |
Open: | $1.7 |
Close: | $1.77 |
High: | $1.775 |
Low: | $1.7 |
Volume: | 17,071 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
News | Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN)
PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that preclinical data and clinical trial design from the study of SON-080 (rec...
2024-03-12 08:28:49 ET More on Pre-market losers & stocks. Renalytix approached by potential buyer, stock rallies 28% Renalytix surges after Medicare draft decision on lead product Seeking Alpha’s Quant Rating on ASLAN Pharmaceuticals Historical ea...
Message Board Posts | Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN)
Subject | By | Source | When |
---|---|---|---|
WTF, is this an auction? I'll take.25s | Pnypnchr | investorshub | 06/28/2023 9:04:25 PM |
I love selected accounting myself.. $SONN | Carjockey2 | investorshub | 06/28/2023 7:58:53 PM |
Never see you posting on those stocks combined | Carjockey2 | investorshub | 06/28/2023 7:58:08 PM |
LMAO Not for me, it isn't sunshine... Funny how | Carjockey2 | investorshub | 06/28/2023 7:56:57 PM |
Off to where? 22% down. | jonestint | investorshub | 06/28/2023 7:53:27 PM |
News, Short Squeeze, Breakout and More Instantly...
Sonnet BioTherapeutics Holdings Inc. Company Name:
SONN Stock Symbol:
NASDAQ Market:
PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that preclinical data and clinical trial design from the study of SON-080 (rec...
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board (DSMB) The adverse event profile and tolerability of SON-080 was consistent with data from previous IL-6 candidates, meeting the Phase...
PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of clinical data on SON-1010 in Frontiers in Immunology . SON-1010, Sonnet's lea...